The percentages of regulator T cells (Treg, CD3+CD4+CD25+FoxP3+), tumor-associated macrophages (TAM, CD11b+Gr-1−Ly6C-F4/80+), polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC, CD11b+Gr-1+Ly6CintLy6G+) and monocytic myeloid-derived suppressor cells (M-MDSC, CD11b+Gr-1+Ly6ChighLy6G-) were obviously increased, while cytotoxic T cells (Cyto T, CD3+CD4−CD8+) were apparently decreased in sorafenib-treated HCC tumors (Fig. 1C, D). This evidence concerns the gene CD4 and neoplasm.